日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development and Characterization of the NISTCHO Reference Cell Line.

NISTCHO参考细胞系的建立和表征

Dahodwala Hussain, Hodzic Irfan, Slesarev Alexei, Cutak Benjamin, Kuzin Alexander, Lal Rahul, Liu Jiajian, Mahon James, Narasimhan Rajagopalan Lakshmi, Onuska Jaya, Ravellette James, Reger Kelsey, Sakurada Sadie, Stewart Floy, Borgschulte Trissa, Cote Colette, Lee Kelvin H, O'Dell William B, Kelman Zvi, Anderson Britta A

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

乐伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌:系统评价和成本效益分析

Fleeman, Nigel; Houten, Rachel; Nevitt, Sarah; Mahon, James; Beale, Sophie; Boland, Angela; Greenhalgh, Janette; Edwards, Katherine; Maden, Michelle; Bhattacharyya, Devarshi; Chaplin, Marty; McEntee, Joanne; Chow, Shien; Waddell, Tom

Estimation of the health economic benefit of widening pulmonary rehabilitation uptake and completion

评估扩大肺康复参与率和完成率所带来的健康经济效益

Steiner, Michael; Mahon, James; Fuld, Jonathan; Hex, Nick

Estimating the cost due to resistance against antiretroviral therapies in individuals with HIV: Perspective of the Kingdom of Saudi Arabia

估算艾滋病毒感染者抗逆转录病毒疗法耐药性造成的成本:沙特阿拉伯王国的视角

Ghassan, Wali; Basem, Alraddadi; Hawra, Albayat; Ahmad, Alharbi; Muaddi, Abdulrahman Ahmed Hasan; Mestouri, Asma; Elaraby, Rezk; Mahon, James

Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation

磁共振成像技术在非酒精性脂肪性肝病患者诊断准确性和临床影响:系统评价和经济评估

Bresnahan, Rebecca; Duarte, Rui; Mahon, James; Beale, Sophie; Chaplin, Marty; Bhattacharyya, Devarshi; Houten, Rachel; Edwards, Katherine; Nevitt, Sarah; Maden, Michelle; Boland, Angela

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

曲妥珠单抗德鲁替康用于治疗接受过两种或两种以上抗HER2疗法后仍无法切除或转移的HER2阳性乳腺癌:NICE单一技术评估的证据审查组观点

Houten, Rachel; Fleeman, Nigel; Mahon, James; Chaplin, Marty; Edwards, Katherine; Beale, Sophie; Boland, Angela; Dundar, Yenal; Marsden, Ashley; Malik, Zafar; Palmieri, Carlo

Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

用于治疗无症状脊髓性肌萎缩症的Onasemnogene Abeparvovec:外部评估小组对NICE高度专业化技术评估15部分审查的视角

Chaplin, Marty; Bresnahan, Rebecca; Fleeman, Nigel; Mahon, James; Houten, Rachel; Beale, Sophie; Boland, Angela; Dundar, Yenal; Marsden, Ashley; Munot, Pinki

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

培塞他考普兰治疗阵发性睡眠性血红蛋白尿:NICE单一技术评估的证据审查小组观点

Bresnahan, Rebecca; Houten, Rachel; Greenhalgh, Janette; Nevitt, Sarah; Mahon, James; Beale, Sophie; Boland, Angela; Bhattacharyya, Devarshi; Dundar, Yenal; McEntee, Joanne; Gandhi, Shreyans; Fleeman, Nigel; Chaplin, Marty

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

更正:用于治疗症状前脊髓性肌萎缩症的Onasemnogene Abeparvovec:NICE高度专业化技术评估15部分审查的外部评估小组观点

Chaplin, Marty; Bresnahan, Rebecca; Fleeman, Nigel; Mahon, James; Houten, Rachel; Beale, Sophie; Boland, Angela; Dundar, Yenal; Marsden, Ashley; Munot, Pinki

Frequency of inter-specialty consensus decisions and adherence to advice following discussion at a weekly neurovascular multidisciplinary meeting

每周神经血管多学科会议讨论后,跨学科共识决策的频率以及对建议的遵循情况

Offiah, Chika; Tierney, Sean; Egan, Bridget; Collins, Ronán D; Ryan, Daniel J; McCarthy, Allan J; Smith, Deirdre R; Mahon, James; Boyle, Emily; Delaney, Holly; O 'Donohoe, Rory; Hurley, Alison; Walsh, Richard A; Murphy, Sinead M; Bogdanova-Mihaylova, Petya; O 'Dowd, Sean; Kelly, Mark J; Omer, Taha; Coughlan, Tara; O'Neill, Desmond; Martin, Mary; Murphy, Stephen J X; McCabe, Dominick J H